In an IOL.co.za article by Vuyile Madwantsi, published on 20 April 2026, the global conversation around mental health treatment is described as shifting — and rapidly. The recent signing of a US executive order directing regulators to fast-track research into psychedelic substances like psilocybin, MDMA and ibogaine has sent ripples through the psychiatric and broader medical community worldwide. As a psychiatrist practising in South Africa, I think it’s important to address this development with both openness and caution.
A Growing Mental Health Crisis
The scale of the problem we’re trying to solve cannot be overstated. More than 350 million people worldwide live with depression, and over 374 million suffer from anxiety disorders. Traditional treatments — while effective for many — leave a significant number of patients without adequate relief. It is against this backdrop that psychedelic-assisted therapy is gaining renewed scientific interest.
What Are the Substances Being Studied?
Three compounds are at the centre of current research:
- Psilocybin (the active compound in “magic mushrooms”) is being studied for treatment-resistant depression, PTSD, addiction and anxiety related to chronic illness. Countries like Canada, Switzerland and New Zealand already permit limited therapeutic use under strict conditions.
- MDMA has shown potential in helping patients with PTSD feel emotionally safe enough to revisit and process traumatic memories during psychotherapy — though the US FDA declined to approve it in 2024 due to safety and data concerns.
- Ibogaine, derived from a West African plant, is being explored for opioid addiction and PTSD, with some patients reporting significant reductions in withdrawal symptoms and trauma responses.
My Clinical Perspective
While the clinical trials show genuine promise, we must be extremely careful. Without strict medical supervision, these substances can be incredibly dangerous. We aren’t simply talking about discomfort or anxiety — we are talking about serious physical risks including fatal heart rhythm changes, tremors and respiratory failure.
For high-risk groups — including pregnant women, individuals with a history of psychosis, or those with heart conditions — the consequences of unregulated use could be devastating. The potential for emotional instability, suicidal ideation and sudden cardiac arrest is real and must not be minimised in the excitement of emerging research.
The Bottom Line
Psychedelics are not DIY wellness tools. The promising results we are seeing in clinical trials come from controlled, medically supervised environments with carefully screened patients and precise dosing protocols. Recreational or unsupervised use carries a very different risk profile entirely.
South Africa has not yet moved to legalise psychedelics for therapeutic use, though it is worth noting that ketamine — while not a psychedelic — is already being used legally and with some success in certain medical settings here.
The science is accelerating. The policy conversation is shifting. And as clinicians, our responsibility is to stay informed, remain evidence-based and advocate for our patients’ safety above all else.
I encourage you to read the full article that prompted this discussion, and to follow the evidence as it continues to develop.
– Dr Melané van Zyl is a psychiatrist and member of the South African Society of Psychiatrists.
READ THE FULL ARTICLE HERE
“Psychedelics in mental health: benefits, risks and the future of treatment”
